Organogenesis (ORGO) Competitors $4.04 -0.09 (-2.18%) Closing price 10/9/2025 04:00 PM EasternExtended Trading$4.00 -0.04 (-0.87%) As of 04:22 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ORGO vs. NTLA, OCUL, ANIP, VERA, TWST, DYN, APGE, COGT, TLRY, and ABCLShould you be buying Organogenesis stock or one of its competitors? The main competitors of Organogenesis include Intellia Therapeutics (NTLA), Ocular Therapeutix (OCUL), ANI Pharmaceuticals (ANIP), Vera Therapeutics (VERA), Twist Bioscience (TWST), Dyne Therapeutics (DYN), Apogee Therapeutics (APGE), Cogent Biosciences (COGT), Tilray Brands (TLRY), and AbCellera Biologics (ABCL). These companies are all part of the "pharmaceutical products" industry. Organogenesis vs. Its Competitors Intellia Therapeutics Ocular Therapeutix ANI Pharmaceuticals Vera Therapeutics Twist Bioscience Dyne Therapeutics Apogee Therapeutics Cogent Biosciences Tilray Brands AbCellera Biologics Intellia Therapeutics (NASDAQ:NTLA) and Organogenesis (NASDAQ:ORGO) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, dividends, risk, media sentiment, profitability, analyst recommendations and institutional ownership. Do analysts recommend NTLA or ORGO? Intellia Therapeutics presently has a consensus price target of $27.95, suggesting a potential upside of 9.78%. Organogenesis has a consensus price target of $7.33, suggesting a potential upside of 81.52%. Given Organogenesis' higher probable upside, analysts plainly believe Organogenesis is more favorable than Intellia Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Intellia Therapeutics 2 Sell rating(s) 6 Hold rating(s) 13 Buy rating(s) 0 Strong Buy rating(s) 2.52Organogenesis 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Which has more volatility and risk, NTLA or ORGO? Intellia Therapeutics has a beta of 2.37, suggesting that its stock price is 137% more volatile than the S&P 500. Comparatively, Organogenesis has a beta of 1.68, suggesting that its stock price is 68% more volatile than the S&P 500. Is NTLA or ORGO more profitable? Organogenesis has a net margin of -1.92% compared to Intellia Therapeutics' net margin of -908.48%. Organogenesis' return on equity of -0.37% beat Intellia Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Intellia Therapeutics-908.48% -57.48% -45.04% Organogenesis -1.92%-0.37%-0.20% Which has stronger earnings and valuation, NTLA or ORGO? Organogenesis has higher revenue and earnings than Intellia Therapeutics. Organogenesis is trading at a lower price-to-earnings ratio than Intellia Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIntellia Therapeutics$52.86M51.71-$519.02M-$4.69-5.43Organogenesis$429.31M1.19$860K-$0.14-28.86 Does the media favor NTLA or ORGO? In the previous week, Intellia Therapeutics had 18 more articles in the media than Organogenesis. MarketBeat recorded 22 mentions for Intellia Therapeutics and 4 mentions for Organogenesis. Organogenesis' average media sentiment score of 0.88 beat Intellia Therapeutics' score of 0.70 indicating that Organogenesis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Intellia Therapeutics 5 Very Positive mention(s) 5 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Organogenesis 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals & insiders hold more shares of NTLA or ORGO? 88.8% of Intellia Therapeutics shares are owned by institutional investors. Comparatively, 49.6% of Organogenesis shares are owned by institutional investors. 3.1% of Intellia Therapeutics shares are owned by insiders. Comparatively, 33.0% of Organogenesis shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. SummaryOrganogenesis beats Intellia Therapeutics on 9 of the 16 factors compared between the two stocks. Get Organogenesis News Delivered to You Automatically Sign up to receive the latest news and ratings for ORGO and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ORGO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ORGO vs. The Competition Export to ExcelMetricOrganogenesisMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$523.92M$2.65B$6.14B$10.64BDividend YieldN/A56.69%5.66%4.69%P/E Ratio-28.8623.7585.7227.64Price / Sales1.19811.76631.45142.60Price / Cash19.79177.3038.3262.20Price / Book1.935.6413.096.79Net Income$860K$32.78M$3.30B$275.88M7 Day Performance-5.83%5.19%3.75%1.84%1 Month Performance-16.87%14.48%10.73%8.84%1 Year Performance39.31%3.73%85.28%36.10% Organogenesis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ORGOOrganogenesis3.8769 of 5 stars$4.04-2.2%$7.33+81.5%+33.8%$523.92M$429.31M-28.86950Analyst ForecastNTLAIntellia Therapeutics3.8906 of 5 stars$20.54+2.9%$27.95+36.1%+44.2%$2.14B$57.88M-4.38600Trending NewsAnalyst ForecastGap UpOCULOcular Therapeutix3.9352 of 5 stars$10.97-3.9%$22.13+101.7%+28.4%$1.99B$56.66M-8.57230Analyst ForecastANIPANI Pharmaceuticals3.752 of 5 stars$92.06+2.7%$97.29+5.7%+60.0%$1.95B$614.38M-119.56600Analyst DowngradeVERAVera Therapeutics2.5901 of 5 stars$30.94+2.7%$63.00+103.6%-21.6%$1.92BN/A-8.6440Positive NewsAnalyst ForecastTWSTTwist Bioscience3.8102 of 5 stars$31.85+2.5%$48.90+53.5%-23.1%$1.88B$312.97M-21.97990Trending NewsAnalyst ForecastInsider TradeDYNDyne Therapeutics3.3639 of 5 stars$12.65-3.1%$34.07+169.3%-54.2%$1.86BN/A-3.28100Analyst ForecastAPGEApogee Therapeutics3.1454 of 5 stars$39.82-0.2%$92.63+132.6%-1.9%$1.84BN/A-9.6491Trending NewsAnalyst ForecastGap UpCOGTCogent Biosciences2.4683 of 5 stars$15.90+0.9%$20.00+25.8%+49.9%$1.79BN/A-8.9380Analyst ForecastHigh Trading VolumeTLRYTilray Brands1.2287 of 5 stars$1.58-2.5%$1.94+22.6%+28.8%$1.78B$821.31M-0.682,842Trending NewsAnalyst ForecastGap UpABCLAbCellera Biologics2.6089 of 5 stars$5.87-0.5%$8.00+36.3%+137.3%$1.76B$28.83M-10.67500Analyst Forecast Related Companies and Tools Related Companies Intellia Therapeutics Alternatives Ocular Therapeutix Alternatives ANI Pharmaceuticals Alternatives Vera Therapeutics Alternatives Twist Bioscience Alternatives Dyne Therapeutics Alternatives Apogee Therapeutics Alternatives Cogent Biosciences Alternatives Tilray Brands Alternatives AbCellera Biologics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ORGO) was last updated on 10/10/2025 by MarketBeat.com Staff From Our PartnersREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | Sponsored1 Hour Once A DayMy top income trading expert, Dave Aquino, just released a 1-hour trading strategy designed specifically to he...Base Camp Trading | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredToo busy for AI trading?Last week, Nvidia and AMD stock soared as export restrictions eased. Nvidia alone gained nearly 5% in a sin...Timothy Sykes | SponsoredHow to Cash In on Trump’s Digital Current - Move By This ThursdayBitcoin Breakout: What Most Investors Are Missing Washington just approved more crypto legislation in 90 da...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Organogenesis Please log in to your account or sign up in order to add this asset to your watchlist. Share Organogenesis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
